<table border="1" cellpadding="3" cellspacing="3" xmlns="urn:hl7-org:v3" xmlns:voc="urn:hl7-org:v3/voc" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<tbody>
<tr>
<td>
<content stylecode="bold">CYP2C19 or CYP3A4 Inducers </content>
</td>
</tr>
<tr>
<td>   Clinical Impact:       </td>
<td>   Decreased exposure of omeprazole when   used concomitantly with strong inducers [see <linkhtml href="#PHARMACOKINETICS">Clinical Pharmacology (12.3)</linkhtml>].   </td>
</tr>
<tr>
<td>   Intervention:       </td>
<td>   St. John’s Wort, rifampin: Avoid   concomitant use with omeprazole [see <linkhtml href="#_413772a0-73c9-3c7e-9b94-28ffb4eba2fc">Warnings and Precautions (5.9)</linkhtml>].   Ritonavir-containing products: see   prescribing information for specific drugs.    </td>
</tr>
<tr>
<td>    <content stylecode="bold">CYP2C19 or CYP3A4 Inhibitors</content>
</td>
</tr>
<tr>
<td>   Clinical Impact:   </td>
<td>   Increased exposure of omeprazole [see   <linkhtml href="#PHARMACOKINETICS">Clinical Pharmacology (12.3)</linkhtml>].   </td>
</tr>
<tr>
<td>   Intervention:       </td>
<td>   Voriconazole: Dose adjustment of omeprazole   is not normally required. However, in patients with Zollinger-Ellison   syndrome, who may require higher doses, dose adjustment may be considered.   See prescribing information for voriconazole.    </td>
</tr>
</tbody>
</table>